ZIM
MDGL icon

Zacks Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Zacks Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,526
Closed -$68K – 653
2015
Q4 		$68K Buy
+5,526
New +$152K ﹤0.01% 551

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zacks Investment Management's MDGL Position: Q1 2016 in Review

Zacks Investment Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2016, closing a stake of 5,526 shares — an estimated $68K sold.

Zacks Investment Management first reported a position in MDGL in Q4 2015 and held it in 1 quarter. The position peaked at $68K in Q4 2015. 68 funds tracked by Wall St. Rank hold MDGL as of Q1 2016.

  • Zacks Investment Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Zacks Investment Management sold 5,526 Madrigal Pharmaceuticals shares in Q1 2016, an estimated $68K.
  • Zacks Investment Management first reported a position in Madrigal Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Zacks Investment Management's Madrigal Pharmaceuticals position peaked at $68K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2016.

Based on Zacks Investment Management's 13F filing for Q1 2016, filed 12 May 2016.